SITC's Guide to Managing Immunotherapy Toxicity

The Society for Immunotherapy of Cancer's handbook, SITCs Guide to Managing Immunotherapy Toxicity, is a practical reference to managing side effects associated with FDA-approved cancer immunotherapy drugs. It is divided into two parts, with Part I covering immune checkpoint inhibitors and Part II focusing on common and uncommon toxicities. Chapters are written by world-recognized leaders in the immuno-oncology field and provide thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors.

Format: Paperback / softback
Length: 250 pages
Publication date: 30 March 2019
Publisher: Springer Publishing Co Inc

The Society for Immunotherapy of Cancer's handbook, titled "SITCs Guide to Managing Immunotherapy Toxicity," serves as a valuable resource for effectively managing the side effects associated with FDA-approved cancer immunotherapy drugs. Divided into two parts, Part I offers comprehensive chapter-based overviews of immune checkpoint inhibitors in clinical practice. It begins with an introduction to anti-CTLA4 agents, anti-PD1/PD-L1 agents, and approved immunotherapeutic combinations. These chapters delve into the relevant mechanisms of action, indications, and toxicities observed in combating early, advanced, and metastatic stages of cancer in patients.

Part II of the handbook is organized by common and uncommon toxicities that impact major organ systems throughout the body. It begins with a general summary of principles and management options, followed by chapters dedicated to specific toxicities such as rash and mucosal irritation, muscle and joint toxicity, diarrhea and colitis, pneumonitis, endocrine toxicities, neurological toxicities, cardiac toxicity, renal toxicity, hematologic toxicity, and ocular toxicities. Each chapter provides detailed guidance on assessing and treating toxicity, as well as supporting patients through acute and chronic effects. Detailed summary tables are included for quick reference.

Part II concludes with chapters addressing the management of special patient populations, including individuals with autoimmune disease and geriatric patients. It also explores treatment and management of fatigue, and a final chapter focuses on the impact of financial toxicity on patients and caregivers. Authored by esteemed experts in the immuno-oncology field, this text offers thorough coverage of the toxicity and management of adverse effects for immune checkpoint inhibitors. It serves as an indispensable resource for clinical oncologists, emergency physicians, and healthcare professionals involved in the care of cancer patients undergoing immunotherapy.

Weight: 340g
Dimension: 127 x 202 x 20 (mm)
ISBN-13: 9780826172143